- <![CDATA[Dr Cirstea on Sequencing Considerations in R/R Multiple Myeloma]]><![CDATA[Diana Cirstea, MD, discusses sequencing considerations in relapsed/refractory multiple myeloma in the era of T-cell–redirecting therapies.]]>onclive · 2mo ago↗ source
- <![CDATA[Dr Hafron on the FDA Approval of Adjuvant Atezolizumab in MRD+ MIBC]]><![CDATA[Jason Hafron, MD, discusses the significance of the FDA approval of adjuvant atezolizumab for MRD+ muscle-invasive bladder cancer.]]>onclive · 2mo ago↗ source
- <![CDATA[Durvalumab Plus BCG Reduces High-Risk NMIBC Recurrence or Death Risk by 32% in Phase 3 POTOMAC Trial]]><![CDATA[Durvalumab plus BCG induction and maintenance yielded an HR of 0.68 vs BCG alone for DFS in BCG-naive, high-risk non–muscle-invasive bladder cancer.]]>